



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**8 March 2021**

---

## **Bionomics Limited Announces Non-Renounceable Entitlement Offer**

Bionomics Limited (ASX: BNO) (**Bionomics** or **Company**), a clinical stage biopharmaceutical company, is pleased to announce a pro rata non-renounceable 1:6 entitlement offer of new fully paid ordinary shares in the Company (**New Shares**) to raise up to approximately A\$20,000,000 (before costs) (**Entitlement Offer**).

The Entitlement Offer provides eligible shareholders with the opportunity to acquire New Shares at an offer price of A\$0.145 per New Share (**Offer Price**). The Offer Price represents a discount of 44% to the theoretical ex-rights price (TERP)<sup>1</sup> of \$0.26 as at Friday 5 March 2021 and a discount of 48% to the closing price of Bionomics shares on Friday 5 March 2021 being \$0.28.

The Offer Price is the same as the issue price for Bionomics' recently subscribed underwritten placement (refer ASX announcements dated 9 February 2021 and 2 March 2021), extending an opportunity to subscribe for shares at that price to all Bionomics shareholders.

The Entitlement Offer is anticipated to open on 16 March 2021 and close at 5.00pm (Adelaide time) on 30 March 2021 (unless extended) and will, if fully subscribed, result in the issue of approximately 140,922,476 New Shares.

Entitlements to subscribe for New Shares under the Entitlement Offer are non-renounceable and cannot be traded.

Each New Share will rank equally with existing shares on issue. Bionomics will apply for quotation of the New Shares on ASX.

The Entitlement Offer is not underwritten.

Funds raised pursuant to the Entitlement Offer will be used to partly fund a second Phase 2 trial by Bionomics in Post-Traumatic Stress Disorder and for general working capital purposes.

### **Entitlement Offer**

Eligible shareholders with a registered address in Australia or New Zealand as at 6.30pm (Adelaide time) on 11 March 2021 (**Record Date**) will be invited to participate in the Entitlement Offer. The Entitlement Offer is expected to open on 16 March 2021 and to close at 5.00pm (Adelaide time) on 30 March 2021 (**Offer Period**).

---

<sup>1</sup> The Theoretical Ex-Rights Price (**TERP**) is the theoretical price at which Bionomics shares should trade after the ex-date for the Entitlement Offer. TERP is a theoretical calculation only and the actual price at which Bionomics shares trade immediately after the ex-date of the Entitlement Offer will depend on many factors and may not be equal to TERP. TERP is calculated by adjusting for the bonus-element of the Entitlement Offer based on the closing price of Bionomics shares on Friday 5 March 2021.

Eligible shareholders can choose to take up all, part, or none of their entitlements. Eligible shareholders who take up their full entitlement will also be permitted to apply for New Shares in excess of their entitlement at the Offer Price (**Oversubscription Facility**) up to a maximum equivalent to 100% of their entitlement under the Entitlement Offer. There is no guarantee that applicants under the Oversubscription Facility will receive all or any of the additional New Shares for which they apply.

Directors and related parties of Bionomics are not eligible to participate in the Oversubscription Facility.

Further details about the Entitlement Offer will be set out in a booklet (**Offer Booklet**), lodged with ASX today and which Bionomics expects to despatch on 16 March 2021.

Shareholders with a registered address outside Australia or New Zealand on the Record Date are ineligible to participate in the Entitlement Offer.

### Indicative Timetable

The indicative key dates for the Entitlement Offer are as follows:

Event	Date
Announcement of Entitlement Offer	8 March 2021
Record Date for Entitlement Offer	6.30pm (Adelaide time), 11 March 2021
Offer Booklet (including Entitlement and Acceptance Form) despatched and Entitlement Offer opens	16 March 2021
Entitlement Offer closes	5.00pm (Adelaide time), 30 March 2021
Announcement of results of Entitlement Offer	6 April 2021
Allotment of New Shares under the Entitlement Offer	8 April 2021
Commencement of trading of New Shares issued under the Entitlement Offer	9 April 2021

All dates and times are subject to change. Bionomics reserves the right to amend at any time any or all of these dates and times or to withdraw the Entitlement Offer, subject to the Corporations Act, the ASX Listing Rules and other applicable laws. In particular, Bionomics reserves the right to extend the closing date for the Entitlement Offer, or to accept late applications under the Entitlement Offer without prior notice.

### Investor enquiries

If you have any questions in relation to the Entitlement Offer, please contact the Bionomics Offer Information Line on 1300 556 161 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30 am and 5.00 pm (Adelaide time) Monday to Friday.

Nothing contained in this announcement constitutes investment, legal, tax or other advice. You should make your own assessment and consult your independent broker, solicitor, accountant, financial adviser, or other professional adviser in relation to the information in this announcement and any action to be taken on the basis of that information.

### AUTHORISED BY THE BOARD

#### FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
Bionomics Limited  
31 Dalgleish St, Thebarton, South Australia  
+61 8 8354 6100  
[jmoschakis@bionomics.com.au](mailto:jmoschakis@bionomics.com.au)

### **About Bionomics Limited**

Bionomics Limited (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co in the US and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

[www.bionomics.com.au](http://www.bionomics.com.au)

### **Factors Affecting Future Performance**

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.